The pharmacokinetics of sparsentan are presented as geometric mean (% coefficient of variation) unless otherwise specified. The Cmax and AUC of sparsentan increase less than proportionally following administration of single doses of 200 mg to 1600 mg. Sparsentan showed time-dependent pharmacokinetics which may be related to the drug inducing its own metabolism over time. Steady-state plasma levels are reached within 7 days with no accumulation of exposure at the approved recommended dosage. Following a single oral dose of 400 mg sparsentan, the mean Cmax and AUC are 7.0 μg/mL and 83.0 μg×h/mL, respectively. Following daily doses of 400 mg sparsentan, the steady-state mean Cmax and AUC are 6.5 μg/mL and 63.6 μg×h/mL, respectively.
Following a single oral dose of 800 mg sparsentan, the mean Cmax and AUC were 8.6 μg/mL and 161 μg×h/mL, respectively. Following daily doses of 800 mg sparsentan, the steady-state mean Cmax and AUC are 9.8 μg/mL and 96.9 μg×h/mL, respectively.
Results were comparable when FILSPARI was administered orally as a whole tablet or as a crushed tablet in water.
Absorption
Following a single oral dose of sparsentan, the median (minimum to maximum) time to peak plasma concentration is approximately 3 hours (2 to 8 hours).
Effect of Food
Sparsentan AUC and Cmax increased by 22% and 108%, respectively, following administration of a single oral 800 mg dose with a high fat, high calorie meal (1000 kcal, 50% fat) [see Dosage and Administration (2.5)]. No clinically significant differences in sparsentan pharmacokinetics were observed following administration of a single 200 mg dose with a high fat, high calorie meal.
Distribution
The apparent volume of distribution for sparsentan at steady state is 61.4 L at 400 mg and 86.5 L at 800 mg, respectively.
Sparsentan is >99% bound to human plasma proteins.
Elimination
The clearance of sparsentan is time-dependent which may be related to the drug inducing its own metabolism over time. The apparent clearance (CL/F) of sparsentan is 3.88 L/h following the initial 400 mg dose then increases to 5.11 L/h at steady state. The apparent clearance (CL/F) of sparsentan is 5.47 L/h following the initial 800 mg dose then increases to 7.21 L/h at steady state.
The half-life of sparsentan is estimated to be 9.6 hours at steady state.
Metabolism
Cytochrome P450 3A is the major isozyme responsible for the metabolism of sparsentan.
Excretion
After a single dose of radiolabeled sparsentan 400 mg to healthy subjects, approximately 80% of the dose was recovered in feces (9% unchanged) and 2% in urine (negligible amount unchanged). 82% of the dosed radioactivity was recovered within a 10-day collection period.
Specific Populations
No clinically significant differences in the pharmacokinetics of sparsentan were observed based on age (8 – 75 years), sex, race, mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m2), or mild to moderate hepatic impairment (Child-Pugh class A or B). Patients with severe hepatic impairment (Child-Pugh class C) and eGFR <30 mL/min/1.73 m2 have not been studied.
Drug Interaction Studies
Clinical Studies and Model-Informed Approaches
Effect of Other Drugs on Sparsentan
Strong CYP3A inhibitors: Concomitant use with itraconazole (strong CYP3A inhibitor) increased sparsentan Cmax by 25% and AUC by 174%.
Moderate CYP3A inhibitors: Concomitant use with cyclosporine (moderate CYP3A inhibitor) increased sparsentan Cmax by 41% and AUC by 70%.
Strong CYP3A inducers: Coadministration of rifampin (strong CYP3A inducer) is predicted to decrease sparsentan Cmax by 23% and AUC0-inf by 47% at steady state.
No clinically significant difference was observed in the pharmacokinetics of sparsentan when co-administered with esomeprazole (proton pump inhibitor).
Effect of Sparsentan on Other Drugs
CYP2C9 substrates: Concomitant use with sparsentan decreased the exposure of tolbutamide (CYP2C9 substrate) Cmax by 9% and AUC0-inf by 25%.
CYP2C19 substrates: Concomitant use with sparsentan decreased the exposure of omeprazole (CYP2C19 substrate) Cmax by 49% and AUC0-inf by 60%.
CYP2B6 substrates: Concomitant use with sparsentan decreased the exposure of bupropion (CYP2B6 substrate) Cmax by 32% and AUC0-inf by 33%.
P-gp substrates: Concomitant use with sparsentan increased the exposure of digoxin (P-gp substrate) Cmax by 61% and AUC0-inf by 18%.
No clinically significant differences in the pharmacokinetics of midazolam (CYP3A4 substrate), pitavastatin (OATP1B1 and OATP1B3, substrate), or rosuvastatin (BCRP substrate) were observed when co-administered with sparsentan. In addition, sparsentan had no clinically significant effect on serum creatinine levels (an endogenous biomarker of OAT2, OCT2, MATE1, and MATE2K) or on 6β‑hydroxycortisol (an endogenous biomarker of OAT3).